Revenue distribution by sectors:

• Pharmaceutical products: approx. 70%
• Ophthalmology: approx. 20%
• Health products: approx. 10%

TOP 3 markets and their percentage shares:

• China: approx. 60%
• Asia (excluding China): approx. 20%
• North America: approx. 10%

Chengdu Kanghong Pharmaceutical Group Co., Ltd. generates the majority of its revenue from the manufacturing and distribution of pharmaceutical products, with a significant portion attributed to ophthalmology. The primary market is China, followed by other Asian countries and North America. These markets are crucial for the company's growth, especially due to the increasing demand for specialized pharmaceutical solutions.

Production Sites: Chengdu, China

Chengdu Kanghong Pharmaceutical Group Co., Ltd mainly produces its products in Chengdu, China. The company has its main production facilities there, which are used for the manufacturing of pharmaceutical products and medical devices. Chengdu is a central location for the company as it is well connected both logistically and infrastructurally.

Revenue Growth: Estimated at 10-12% annually (2025, based on historical data and market trends)

Research and Development Investments: Over 15% of revenue (2025, estimated)

Chengdu Kanghong Pharmaceutical Group Co., Ltd pursues a growth strategy strongly focused on innovation and research. The company consistently invests a significant portion of its revenue in research and development to bring new and improved pharmaceutical products to the market. These investments aim to expand the product pipeline and strengthen the market position in the fields of ophthalmology and other specialized therapies.

Another strategic focus is on international expansion. Chengdu Kanghong Pharmaceutical plans to expand its presence in overseas markets, particularly in regions with growing demand for specialized pharmaceutical solutions. This includes establishing new partnerships and exploring new distribution channels.

Additionally, the company is leveraging strategic alliances and collaborations with other pharmaceutical companies and research institutions to harness synergies and facilitate access to new technologies and markets. This strategy is intended to maximize growth potential and enhance competitiveness on a global scale.

Main raw materials: Active ingredients for pharmaceutical products, packaging materials

Import countries: India, Germany, USA

Chengdu Kanghong Pharmaceutical Group Co., Ltd imports a variety of raw materials necessary for the production of their pharmaceutical products. This includes in particular active ingredients, which are often sourced from India, one of the largest producers of pharmaceutical active ingredients worldwide.

In addition, the company imports packaging materials required for the safe and effective packaging of their products. These materials are frequently sourced from Germany and the USA, known for their high-quality packaging technologies.

Relying on imports from these countries enables Chengdu Kanghong to ensure the quality and effectiveness of their products by adhering to internationally recognized standards and technologies.

Market share in China: 5% (estimated, 2025)
R&D investments: 10% of revenue (2024)
Revenue growth: 8% (2024)

Chengdu Kanghong Pharmaceutical Group Co., Ltd has established itself as a significant player in the Chinese pharmaceutical market in recent years. The company benefits from a diversified product portfolio that includes both patented drugs and generics. A key competitive advantage lies in the continuous investments in research and development, which account for around 10% of revenue. This enables the company to develop and bring innovative products to the market.

Furthermore, Chengdu Kanghong has a strong presence in the field of ophthalmic drugs, giving them a niche position in a growing market segment. The strategic focus on specific therapy areas and the ability to quickly respond to market changes strengthen their competitive advantage over other pharmaceutical companies in China.

Institutional Investor Share: Estimated around 25-30% (2025)

Insider Trades: No specific current data available (2025)

The institutional investor share in Chengdu Kanghong Pharmaceutical Group Co., Ltd is estimated to be around 25-30%. This estimate is based on typical ownership structures of comparable companies in the industry and region.

There is currently no specific current data available on insider trades. Typically, such information is disclosed in annual reports or through regulatory filings. It is advisable to consult the latest company reports or stock exchange announcements to obtain detailed information.

Market share of Chengdu Kanghong Pharmaceutical Group Co., Ltd: Estimate: 4.5% (2025)

Top competitors and their market shares:

1. Sino Biopharmaceutical Limited: 8.2%
2. Jiangsu Hengrui Medicine Co., Ltd.: 7.9%
3. Shanghai Pharmaceuticals Holding Co., Ltd.: 6.5%
4. China Resources Pharmaceutical Group Limited: 5.8%
5. Chengdu Kanghong Pharmaceutical Group Co., Ltd.: 4.5%
6. Tasly Pharmaceutical Group Co., Ltd.: 4.0%
7. Fosun Pharma: 3.7%
8. Yunnan Baiyao Group Co., Ltd.: 3.5%
9. Livzon Pharmaceutical Group Inc.: 3.2%
10. Tonghua Dongbao Pharmaceutical Co., Ltd.: 3.0%

Chengdu Kanghong Pharmaceutical Group Co., Ltd. has a moderate market share compared to its competitors. The company's moat is mainly based on its specialization in ophthalmological research and development, particularly in the field of ophthalmology, where it offers innovative products.

In comparison to leading companies like Sino Biopharmaceutical Limited and Jiangsu Hengrui Medicine Co., Ltd., which have a broader product portfolio and larger financial resources, Chengdu Kanghong's moat is less pronounced. These larger companies often have advantages in scaling, research and development, and global market presence.

However, Chengdu Kanghong can maintain a significant competitive advantage through its niche focus and continuous innovation in specific therapeutic areas. In the long term, diversifying the product portfolio and expanding internationally could further strengthen the company's moat.

Revenue Growth: 10.5% (2024) Research and Development Ratio: 12% of revenue (2024) Market Share in China: 5% in the field of ophthalmological drugs (2024)

Chengdu Kanghong Pharmaceutical Group Co., Ltd recorded a revenue growth of 10.5% in 2024, indicating strong demand for their products, especially in the field of ophthalmological drugs. The company continues to invest heavily in research and development, with a ratio of 12% of revenue. This suggests that the company is striving to strengthen its market position through innovations and new products.

The 5% market share in the field of ophthalmological drugs in China shows that Chengdu Kanghong plays a significant role in this segment. This offers potential for further growth, especially if the company expands its product range or enters new markets.

Overall, the combination of solid revenue growth, high investment in research and development, and a stable market share suggests that Chengdu Kanghong Pharmaceutical Group Co., Ltd could be a promising investment, especially for investors interested in long-term growth.

Dividend Yield: 2.5% (2025, estimated)
Dividend History: Regular payouts over the last 5 years

Chengdu Kanghong Pharmaceutical Group Co., Ltd has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield for 2025 is around 2.5%, based on current market conditions and past payouts.

The company has followed a stable dividend policy in the past, suggesting its commitment to providing continuous returns to its shareholders. Analysts expect this practice to continue unless significant market changes or company-specific challenges arise.